This inventor holds 3 USPTO granted patents. Top assignee: University of Illinois. Active years: 2008-2013.
Location History:
- Goettingen, DE (2008 - 2010)
- Göttingen, DE (2013)
Company Filing History:
Years Active: 2008-2013
Title: Manfred Konrad: Innovator in Enzyme Engineering
Introduction
Manfred Konrad is a distinguished inventor based in Göttingen, Germany. He has made significant contributions to the field of biochemistry, particularly in the development of engineered enzymes that enhance the efficacy of prodrugs used in cancer treatment. His innovative work has led to the filing of multiple patents, showcasing his commitment to advancing medical science.
Latest Patents
Manfred Konrad holds 3 patents that focus on the use of specifically engineered enzymes to improve the effectiveness of prodrugs. One of his notable inventions provides methods for enhancing the efficiency of prodrugs through the use of engineered enzymes with altered or enhanced activity. These enzymes exhibit broader substrate specificity towards nucleoside analogs utilized in cancer chemotherapy. The invention also includes modified deoxycytidine kinase (dCK) mutants with enhanced activities, as well as antibody-conjugated enzymes that can be specifically delivered to tumor cells. Another patent emphasizes the delivery of these enzymes to specific target cells in patients, further improving treatment outcomes.
Career Highlights
Manfred Konrad is affiliated with the University of Illinois, where he continues to conduct research and develop innovative solutions in the field of cancer treatment. His work has garnered attention for its potential to significantly impact therapeutic strategies for patients suffering from various forms of cancer.
Collaborations
Throughout his career, Manfred has collaborated with notable colleagues, including Arnon Lavie and Farhad Ravandi. These partnerships have fostered a collaborative environment that enhances the research and development of new therapeutic approaches.
Conclusion
Manfred Konrad's contributions to enzyme engineering and prodrug efficacy represent a significant advancement in cancer treatment. His innovative patents and collaborative efforts continue to pave the way for future breakthroughs in medical science.